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Objective. To study the prevalence of epistaxis in visceral leismaniasis and its correlation with hematological proﬁle. Methods.O u t
of 80 diagnosed cases of visceral leishmaniasis, 19 patients with epistaxis were included in the study. Diagnosis was made by Rk-39
fromperipheralsmearandLDbodiesfrombonemarrow.Beforestartinganti-kala-azartreatment,nasalexaminationﬁndingsand
hematological proﬁle were noted. Study Design. Prospective cross-sectional hospital-based study. Results. Epistaxis was found in
the age group of 7–66 years. Epistaxis was observed in 19 (23.8%) cases. One patient died because of epistaxis and neck hematoma.
Conclusion. Epistaxis is a common ENT ﬁnding in endemic area of visceral leishmaniasis like our case.
1.Introduction
Leishmaniasis refers to the spectrum of diseases caused
by Leishmania species, which are Protozoa of order Kine-
toplastida. Clinically leishmaniasis is divided into visceral
(kala-azar), cutaneous, mucosal, and mucocutaneous syn-
dromes and PKDL. Kala-azar is most commonly caused by
L. donovani, L. infantum, and L. chagasi [1–3].
Visceral leishmaniasis has been reported from >60 coun-
tries[3]. An estimated 500000 persons are aﬀected by viscer-
al leishmaniasis every year worldwide. The vast major-
ity of these cases (90%) occur in poor rural area
of India, Bangladesh, Sudan, Brazil, and Nepal [4, 5].
L.donovaniisresponsibleforvisceralleishmaniasisineastern
India, Bangladesh, Nepal, and vast areas of East Africa [1, 3].
Visceral leishmaniasis (VL) is a major public health
problem in Nepal. The disease is endemic in twelve terai
districts of eastern and southern Nepal. It is estimated that
more than 6 million people in Nepal are at risk of leishmania
infection [1].
Diﬀerent otorhinolaryngological manifestations are seen
in leishmaniasis. One of the common ﬁndings is epistaxis.
Prevalence of epistaxis in visceral leishmaniasis up to 51%
was found in Sudan and the Mediterranean littoral area [6].
The exact prevalence and cause of epistaxis was not clear in
oursetup.Thisstudywasdonetoﬁndouttheprevalenceand
hematological risk factor of epistaxis among VL patients.
2.MaterialsandMethods
This study was conducted at Department of Otolaryngology
and Head and Neck Surgery and Department of Internal
MedicineinB.P.KoiralaInstituteofHealthSciencesDharan,
NepaloveraperiodofoneyearfromJanuary2007toJanuary
2008. It was a hospital-based prospective cross-sectional
study. The total of 80 cases of VL was followed in the study
period. VL was diagnosed based on clinical proﬁle and the
presence of Rk-39 from peripheral smear and LD bodies
frombonemarrowortissuebiopsy.Beforestartinganti-kala-
azartreatment,nasalexamination ﬁnding andhematological
proﬁle were noted. The other appropriate diagnostic test was
done as necessary. Finally, data analysis was done by using
SPSS 12.0 version.
Inclusion criteria were the following.
(i) All the diagnosed cases of visceral leishmanias that
presented with epistaxis.
(ii) Either of sex.2 International Journal of Otolaryngology
Exclusion criteria were the following.
(i) Patient already on anti-VL treatment.
(ii) Anyotherestablishedcondition/comorbiditiesgiving
rise to similar manifestation.
(iii) Patient not willing to participate in the study.
3. Results
This study includes a total of 80 diagnosed cases of visceral
leishmaniasis. Nasal bleeding was found in 19 (23.8%) cases
with age ranging from 7 to 66 years and median age 31.85 ±
12.15 years. 13 (68.5%) cases were males and 6 (31.5%)
were females. Male-to-female ratio was 2.17:1 (Table 1).
Unilateral bleeding was seen in 11 (57.9%) cases, whereas
bilateral bleeding was seen in 8 (42.1%) cases (Table 2).
Fourteen (74%) cases were anterior type and 5 (26%) were
posterior (Table 3). Sixteen (84.2%) of epistaxis patients had
Hb <10gm/dL with mean 8.1gm/dL, 17 (89.5%) had total
leucocytecount<4000withmean2940/mm3,and19(100%)
had platelet count <1500000 with mean 81526/mm3 at
presentation(Table 4).MeanPTwas16.5andINR1.35.Four
(21.1%)hadINR>1.6atpresentation.Onunivariateanalysis
epistaxis was signiﬁcantly correlated with thrombocytopenia
(P = 0.021) (Table 5).
4. Discussion
Leishmaniasis is caused by infection with parasites of the
genus Leishmania. Leishmaniasis is not a single disease but
a “variety of syndromes” that are complex and cosmopolitan
[6]. Visceral leishmaniasis is caused by L. donovani which is
endemic in eastern terai of Nepal [7].
Diﬀerent types of ENT manifestation were found in
visceral leishmaniasis. One of the common manifestations is
epistaxis. Prevalence of epistaxis in visceral leishmaniasis was
around51%inSudanandtheMediterraneanlittoralarea[6]
and 47–88% in the study of Zijlstra and EL-Hassan [8]. In
our study it was only 23.8%, it may be due to the diﬀerent
zoographical locations and hospital-based study.
Bilateral bleeding occured in 11 (57.9%) of cases and
unilateral in 8 (42.1%). Most of the bleeding was of the
anterior type (14 (73.7%) cases). There was no speciﬁc
pattern of bleeding as most of cases had diﬀuse mucosal
bleed.
Anterior epistaxis refers to bleeding point seen on ante-
rior rhinoscopy. Posterior bleeding refers to active bleeding
refractory to adequate anterior packing or when no bleeding
point is identiﬁed on anterior rhinoscopy [9].
The pathogenesis of epistaxis occurring in early phase
of disease is not understood, but that occurring late in the
disease is probably due to a combination of deﬁcient clotting
factor and thrombocytopenia [6, 10].
In our study out of 19 epistaxis patients, 84.2% had
Hb <10gm/dL, 89.5% had TLC <4000/mm3, and 100% had
platelet count <150000/mm3.
Table 1: Gender distribution.
Gender No. of cases Percent (%)
Male 13 68.5
Female 6 31.5
Total 19 100
Table 2: Site of epistaxis.
Laterality No. of cases Percent (%)
Unilateral nostril 11 57.9
Bilateral nostril 8 42.1
Total 19 100
Table 3: Classiﬁcation of epistaxis.
Classiﬁcation No. Percent (%)
Anterior 14 74
Posterior 5 26
Total 19 100
The cause of pancytopenia is multifactorial. Seques-
tration and destruction of erythrocyte [11]a n dh a e m o l y -
sis lead to shortened half-life, iron deﬁciency, and folate
deﬁciency reported [11–13]. Immune lysis and ineﬀective
erythropoiesis may contribute to the anaemia. Neutrophil
and platelets are sequestrated and destroyed prematurely [6].
But it is not known whether the observed neutropenia and
thrombocytopenia is due to increased margination, splenic
sequestration, or an autoimmune process or combination of
those factors [3].
Mean prothrombin time was 16.60 ± 2.8 (range 12–
28). INR was 1.28 ± 0.2 (range 1.0–2.0). Renal function test
(serum urea and creatine) was within normal limits.
Among the patients with epistaxis, mean PT was 16.5
and INR 1.35. Four (21.1%) had INR >1.6 at presentation.
Marginally prolonged prothrombin time has been reported
by EL-Hassan et al. [11].
Epistaxis was correlated with diﬀerent hematological
parameters like haemoglobin, TLC, platelet count, PT, and
INR. Epistaxis was signiﬁcantly correlated with thrombocy-
topenia (P = 0.02).
In our study, all patients were managed initially with
nasal decongestant, though 17 (89%) required chemical
cautery,nasalpackingwithabgel.In7patientsanteriornasal
packing and in 5 patients posterior nasal packing using Foley
catheter were done for the control of nasal bleeding followed
by blood transfusion.
One 23/M had neck hematoma with nasal bleeding.
Incision and drainage were done for neck hematoma.
Posterior nasal packing was done for nasal bleeding. In spite
of blood transfusion and packing, the patient died due to
excessive uncontrollable bleeding.
Bleeding from the anterior nares is one of the least
understood symptoms of VL. The bleeding may be severe
and life threatening. The presence of parasites in the nasal
mucosa may play a role. The bleeding usually responds wellInternational Journal of Otolaryngology 3
Table 4: Hematological proﬁle of epistaxis patients.
Haemoglobin Total leucocyte count Platelet count
Hb (gm/dL) No. of cases % TLC (/mm3) No. of cases % Platelet count (/mm3)N o . o f c a s e s %
>10 3 15.8 >4000 2 10.5 >150000 0 0
<10 16 84.2 <4000 17 89.5 <150000 19 100
Total 19 100 Total 19 100 Total 19 100
Mean Hb = 8.1 (range 5.6–10.56)gm/dL Mean TLC = 2940 Mean platelet count = 81526
Table 5: Univariate analysis: risk factor for epistaxis.
Variable Odds ratio 95% conﬁdence interval P value
Lower Upper
Hb <10gm/dL 1.9 0.48 7.39 0.27
TLC <4000/mm3 1.44 0.42 4.99 0.39
Platelet count <150000 1.39 1.20 1.62 0.02∗
PT >14sec 1.11 0.31 3.91 0.56
INR >1.6 1.82 0.53 6.20 0.33
∗P value < 0.05 signiﬁcant.
to symptomatic therapy (nasal tamponade using gauze with
1% lignocaine) but it often recurs [8].
5. Conclusion
Epistaxis is a common ENT ﬁnding in endemic area of
visceral leishmaniasis. Pancytopenia is a common laboratory
ﬁnding. Epistaxis may be due to thrombocytopenia. Further
studies with larger series of cases and followup are needed to
be taken into consideration.
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